Thursday - December 26, 2024

Formulations and Methods of Use for Alpha Connexin C-Terminal (ACT) Peptides

2024-10-29

ALEXANDRIA, Virginia, Oct. 29 -- XEQUEL BIO, INC., Fort Worth, Texas has been assigned a patent (No. US 12128086 B2, initially filed Oct. 6, 2022) developed by Gautam Ghatnekar, Mt. Pleasant, South Carolina, for "Formulations and methods of use for alpha connexin c-terminal (ACT) peptides." . . .

Information Request Form

Name:
Category that best fits the type of business or agency you are affiliated with:	Government Newspaper / Media Business Public Policy Individual / Student Educators
Company Name:
Email:
Phone:
State:

I'd like to have a copy of this article mailed to me.

To also receive a free sample of other Targeted News products check the appropriate boxes below.
Golf Handicap site (FairwayFiles.com)
Products marked with ** can be customized by keywords or areas of interest. If you select them please specify your keywords in the box below:

If we need to contact you please specify your preferred contact method. Have a representative contact me by phone
Have a representative contact me via email

Additonal questions or comments:

Click here for more information or a free trial

Existing Customer Login

Formulations and Methods of Use for Alpha Connexin C-Terminal (ACT) Peptides

Information Request Form

Copyright Targeted News Service 2024